The overall objective of this project is to identify new, more effective medical countermeasures for the acute seizures produced by organophosphate (OP) anticholinesterase inhibitor and GABAA receptor antagonist chemical threat agents. By preventing or stopping the acute seizures, these countermeasures will improve the survival and long-term outcome of individuals exposed to seizure-inducing doses of these agents. We have selected two OP agents diisopropylfluorophosphate (DFP) and soman (0-pinacolyl methylphosphonofluoridate;GD) and one GABAA receptor antagonist tetramethylenedisulfotetramine (TETS) to represent the two broad classes of chemical threat agents. Soman, a representative of the OP neurotoxin chemical warfare agents (""""""""nerve agents""""""""), is classified as a Schedule 1 substance under the Chemical Weapons Convention of 1993. DFP, while less potent than the nerve agents in the Chemical Weapons Convention toxic chemicals list, has nearly identical effects. As a volatile agent that could rapidly spread inside closed areas, it could cause many injuries and deaths and is therefore a credible threat agent. TETS, a representative of the GABAA receptor antagonist convulsants is a highly lethal toxin that has been used as a rodenticide but is now banned in most countries of the world. Nevertheless, lethal poisoning with TETS occur regularly. On a mg basis, TETS is equal in lethality to the OP chemical warfare agents. Recently, we have had the opportunity to characterize the convulsant activity of TETS in mice and rats when administered by the i.p., i.v., oral and intracerebroventricular routes. As a result of this work, we have developed the first animal model in which to evaluate potential treatments for TETS when administered before and after exposure. In this project, DFP and soman are administered to rats and TETS is administered to mice to induce seizures. The animals are treated before or at various intervals following exposure with various potential therapeutic agents (or combinations) to assess the ability of the test agent to prevent or terminate behavioral or electrographic seizure activity. Testing in the OP models occurs in a step-wise fashion, first against DFP seizures because DFP has reduced safety concerns and can be used in a regular laboratory environment, and then with soman, which requires extreme safety precautions available at the US Army Medical Research Institute of Chemical Defense. All test agents are compared with diazepam, the current standard of care for the emergency treatment of chemical exposure seizures. Diazepam may be effective if administered early in the course of seizures but seizures may recur and the drug may be inactive if administered later in the course of seizures. In addition, diazepam can depress blood pressure and respiration. A further concern is that diazepam is erratically absorbed when administered by the i.m. route (as with the injector systems stockpiled for use in mass casualty situations). We are seeking agents (or combinations) that improve upon diazepam with respect to any of these liabilities. We have identified a series of potential therapies (Tier 1) that are either currently approved for sale in the U.S. or for which human data is available and can therefore be rapidly deployed. In addition, novel potential therapies that are new molecular entities (Tier 2) will be developed in Core B and Project 3. Therapies that exhibit superior activity to diazepam will be studied in Project 2 for their ability to mitigate seizure-induced brain damage. Finally, in order to advance the most promising therapies, we will complete various additional studies, including formulation development and safety, toxicology and ADME studies in conjunction with Cores A and B, to assist in making go/no-go decisions regarding further development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS079202-03
Application #
8730730
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$608,719
Indirect Cost
$209,602
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Lee, Kin Sing Stephen; Henriksen, Niel M; Ng, Connie J et al. (2017) Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase. Arch Biochem Biophys 613:1-11
Wagner, Karen; Gilda, Jennifer; Yang, Jun et al. (2017) Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice. Behav Brain Res 326:69-76
Hwang, Sung Hee; Wagner, Karen; Xu, Jian et al. (2017) Chemical synthesis and biological evaluation of ?-hydroxy polyunsaturated fatty acids. Bioorg Med Chem Lett 27:620-625
Nguyen, Hai M; Singh, Vikrant; Pressly, Brandon et al. (2017) Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Mol Pharmacol 91:392-402
Wagner, K; Lee, K S S; Yang, J et al. (2017) Epoxy fatty acids mediate analgesia in murine diabetic neuropathy. Eur J Pain 21:456-465
Cao, Zhengyu; Xu, Jian; Hulsizer, Susan et al. (2017) Influence of tetramethylenedisulfotetramine on synchronous calcium oscillations at distinct developmental stages of hippocampal neuronal cultures. Neurotoxicology 58:11-22
Chapman, Christopher A R; Wang, Ling; Chen, Hao et al. (2017) Nanoporous Gold Biointerfaces: Modifying Nanostructure to Control Neural Cell Coverage and Enhance Electrophysiological Recording Performance. Adv Funct Mater 27:
Hu, Pingping; Wu, Xiaojuan; Khandelwal, Alok R et al. (2017) Endothelial Nox4-based NADPH oxidase regulates atherosclerosis via soluble epoxide hydrolase. Biochim Biophys Acta 1863:1382-1391
Pressly, Brandon; Nguyen, Hai M; Wulff, Heike (2017) GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Arch Toxicol :
Hobson, Brad A; Sisó, Sílvia; Rowland, Douglas J et al. (2017) From the Cover: MagneticResonance Imaging Reveals Progressive Brain Injury in Rats Acutely Intoxicated With Diisopropylfluorophosphate. Toxicol Sci 157:342-353

Showing the most recent 10 out of 83 publications